Benutzerspezifische Werkzeuge

Solide Tumoren

Diverse: ACT Immatics IMA 201-101

The study purpose is to establish the safety and tolerability of IMA201 in patients with solid tumors that express melanoma-associated antigen 4 and/or 8 (MAGEA4/8).Mehr…

Diverse: ACT Immatics IMA 202-101

Phase 1 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with recurrent and/or refractory solid Tumors.Mehr…

Diverse: BMS CA022-001

Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors.Mehr…

Diverse: ICT01-101

A first-in-human, two-part, open-label, clinical study to assess the saftey, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor, in patients with advanced-stage, relapsed/ refractory cancer (EVICTION ...Mehr…

Diverse: ACT Immatics IMA 203-101

Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Relapsed and/or Refractory Solid Tumors (ACTengine IMA203-101)Mehr…

Diverse: Merck MK 4280-001

A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors.Mehr…